{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T01:40:08Z","timestamp":1780537208065,"version":"3.54.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2013,11,30]],"date-time":"2013-11-30T00:00:00Z","timestamp":1385769600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2014,2]]},"DOI":"10.1007\/s00277-013-1966-z","type":"journal-article","created":{"date-parts":[[2013,11,29]],"date-time":"2013-11-29T06:30:11Z","timestamp":1385706611000},"page":"267-277","source":"Crossref","is-referenced-by-count":14,"title":["Alemtuzumab in chronic lymphocytic leukemia: final results of a large observational multicenter study in mostly pretreated patients"],"prefix":"10.1007","volume":"93","author":[{"name":"for The Austrian Collaborative Study Group on Alemtuzumab in Chronic Lymphocytic Leukemia, in cooperation with The Czech Leukemia Study Group for Life, CELL","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Fiegl","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Stauder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Steurer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Mian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Hopfinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Brychtova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Skrabs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Zabernigg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Schmid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Haslbaur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Winder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Walder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Lang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Voskova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Greil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Mayer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Gastl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,11,30]]},"reference":[{"key":"1966_CR1","doi-asserted-by":"crossref","first-page":"3554","DOI":"10.1182\/blood.V99.10.3554","volume":"99","author":"MJ Keating","year":"2002","unstructured":"Keating MJ, Flinn I, Jain V et al (2002) Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood 99:3554\u20133561","journal-title":"Blood"},{"key":"1966_CR2","doi-asserted-by":"crossref","first-page":"3891","DOI":"10.1200\/JCO.2002.06.119","volume":"20","author":"KR Rai","year":"2002","unstructured":"Rai KR, Freter CE, Mercier RJ et al (2002) Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine. J Clin Oncol 20:3891\u20133897","journal-title":"J Clin Oncol"},{"key":"1966_CR3","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1002\/cncr.22263","volume":"107","author":"M Fiegl","year":"2006","unstructured":"Fiegl M, Falkner A, Hopfinger G et al (2006) Austrian Collaborative Study Group on Alemtuzumab in Chronic Lymphocytic Leukemia. Routine clinical use of alemtuzumab in patients with heavily pretreated B-cell chronic lymphocytic leukemia: a nation-wide retrospective study in Austria. Cancer 107:2408\u20132416","journal-title":"Cancer"},{"key":"1966_CR4","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1080\/10428190310001598017","volume":"45","author":"K Rieger","year":"2004","unstructured":"Rieger K, Von Gr\u00fcnhagen U, Fietz T et al (2004) Efficacy and tolerability of alemtuzumab (CAMPATH-1H) in the salvage treatment of B-cell chronic lymphocytic leukemia\u2014change of regimen needed? Leuk Lymphoma 45:345\u2013349","journal-title":"Leuk Lymphoma"},{"key":"1966_CR5","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1038\/sj.leu.2404435","volume":"20","author":"C Karlsson","year":"2006","unstructured":"Karlsson C, Norin S, Kimby E et al (2006) Alemtuzumab as first-line therapy for B-cell chronic lymphocytic leukemia: long-term follow-up of clinical effects, infectious complications and risk of Richter transformation. Leukemia 20:2204\u20132207","journal-title":"Leukemia"},{"key":"1966_CR6","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1200\/JCO.1997.15.4.1567","volume":"15","author":"A Osterborg","year":"1997","unstructured":"Osterborg A, Dyer MJ, Bunjes D et al (1997) Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia. J Clin Oncol 15:1567\u20131574","journal-title":"J Clin Oncol"},{"key":"1966_CR7","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1002\/cncr.11551","volume":"98","author":"A Ferrajoli","year":"2003","unstructured":"Ferrajoli A, O\u2019Brien SM, Cortes JE et al (2003) Phase II study of alemtuzumab in chronic lymphoproliferative disorders. Cancer 98:773\u2013778","journal-title":"Cancer"},{"key":"1966_CR8","doi-asserted-by":"crossref","first-page":"2971","DOI":"10.1200\/JCO.2005.04.021","volume":"23","author":"P Moreton","year":"2005","unstructured":"Moreton P, Kennedy B, Lucas G et al (2005) Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival. J Clin Oncol 23:2971\u20132979","journal-title":"J Clin Oncol"},{"key":"1966_CR9","doi-asserted-by":"crossref","first-page":"3994","DOI":"10.1200\/JCO.2008.21.1128","volume":"27","author":"S Stilgenbauer","year":"2009","unstructured":"Stilgenbauer S, Zenz T, Winkler D et al (2009) Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol 27:3994\u20134001","journal-title":"J Clin Oncol"},{"key":"1966_CR10","doi-asserted-by":"crossref","first-page":"5616","DOI":"10.1200\/JCO.2007.12.9098","volume":"25","author":"P Hillmen","year":"2007","unstructured":"Hillmen P, Skotnicki AB, Robak T et al (2007) Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia. J Clin Oncol 25:5616\u20135623","journal-title":"J Clin Oncol"},{"key":"1966_CR11","unstructured":"Rai K, Keating MJ, Coutre S et al (2002) Patients with refractory B-CLL and T-PLL treated with alemtuzumab (Campath) on a compassionate basis. A report on efficacy and safety of CAM511 trial. Blood 100:(Abstr 3165)"},{"key":"1966_CR12","doi-asserted-by":"crossref","first-page":"3278","DOI":"10.1182\/blood-2003-10-3729","volume":"103","author":"G Lozanski","year":"2004","unstructured":"Lozanski G, Heerema NA, Flinn IW et al (2004) Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions. Blood 103:3278\u20133281","journal-title":"Blood"},{"key":"1966_CR13","first-page":"1435","volume":"90","author":"NC Osuji","year":"2005","unstructured":"Osuji NC, Del Giudice I, Matutes E et al (2005) The efficacy of alemtuzumab for refractory chronic lymphocytic leukemia in relation to cytogenetic abnormalities of p53. Haematologica 90:1435\u20131436","journal-title":"Haematologica"},{"key":"1966_CR14","unstructured":"Wickramanayake PD, K\u00f6ppler H, Rohrberg R et al (2005) Use of alemtuzumab (MabCampath\u00ae) is safe and effective in an outpatient setting: interim analysis of a postmarketing surveillance. Onkologie 28(suppl3): 86 (Abstract 253)"},{"key":"1966_CR15","first-page":"333","volume":"65","author":"BA Laros-van Gorkom","year":"2007","unstructured":"Laros-van Gorkom BA, Huisman CA, Wijermans PW, Schipperus MR (2007) Experience with alemtuzumab in treatment of chronic lymphocytic leukaemia in the Netherlands. Neth J Med 65:333\u2013338","journal-title":"Neth J Med"},{"key":"1966_CR16","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1080\/10428190701760029","volume":"49","author":"D Hui","year":"2008","unstructured":"Hui D, Lam W, Toze C et al (2008) Alemtuzumab in clinical practice: a British Columbia experience. Leuk Lymphoma 49:218\u2013226","journal-title":"Leuk Lymphoma"},{"key":"1966_CR17","first-page":"549","volume":"55","author":"M Doubek","year":"2009","unstructured":"Doubek M, Jungov\u00e1 A, Brejcha M, Panovsk\u00e1 A, Brychtov\u00e1 Y, Posp\u00edsil Z, Mayer J (2009) Alemtuzumab in chronic lymphocytic leukemia treatment: retrospective analysis of outcome according to cytogenetics. Vnitr Lek 55:549\u2013554","journal-title":"Vnitr Lek"},{"key":"1966_CR18","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1111\/j.1365-2141.2011.08965.x","volume":"156","author":"A Cortelezzi","year":"2011","unstructured":"Cortelezzi A, Gritti G, Laurenti L et al (2011) An Italian retrospective study on the routine clinical use of low-dose alemtuzumab in relapsed\/refractory chronic lymphocytic leukaemia patients. Br J Haematol 156:481\u2013489","journal-title":"Br J Haematol"},{"key":"1966_CR19","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1182\/blood.V98.6.1721","volume":"98","author":"CE Dearden","year":"2001","unstructured":"Dearden CE, Matutes E, Cazin B et al (2001) High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H. Blood 98:1721\u20131726","journal-title":"Blood"},{"key":"1966_CR20","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1046\/j.1365-2141.1997.d01-2061.x","volume":"96","author":"AL Bowen","year":"1997","unstructured":"Bowen AL, Zomas A, Emmett E, Matutes E, Dyer MJ, Catovsky D (1997) Subcutaneous CAMPATH-1H in fludarabine-resistant\/relapsed chronic lymphocytic and B-prolymphocytic leukaemia. Br J Haematol 96:617\u2013619","journal-title":"Br J Haematol"},{"key":"1966_CR21","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1002\/ajh.20843","volume":"82","author":"BT Chaar","year":"2007","unstructured":"Chaar BT, Petruska PJ (2007) Complete response to alemtuzumab in a patient with B prolymphocytic leukemia. Am J Hematol 82:417","journal-title":"Am J Hematol"},{"key":"1966_CR22","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1182\/blood-2012-01-380139","volume":"120","author":"C Dearden","year":"2012","unstructured":"Dearden C (2012) How I treat prolymphocytic leukemia. Blood 120:538\u2013551","journal-title":"Blood"},{"key":"1966_CR23","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1093\/annonc\/mdq236","volume":"21","author":"M Fiegl","year":"2010","unstructured":"Fiegl M, Erdel M, Tinhofer I et al (2010) Clinical outcome of pretreated B-cell chronic lymphocytic leukemia following alemtuzumab therapy: a retrospective study on various cytogenetic risk categories. Ann Oncol 21:2410\u20132419","journal-title":"Ann Oncol"},{"key":"1966_CR24","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1007\/s00277-011-1192-5","volume":"90","author":"M Fiegl","year":"2011","unstructured":"Fiegl M, Falkner F, Steurer M et al (2011) Successful alemtuzumab retreatment in progressive B-cell chronic lymphocytic leukemia: a multicenter survey in 30 patients. Ann Hematol 90:1083\u20131091","journal-title":"Ann Hematol"},{"key":"1966_CR25","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1038\/leu.2009.146","volume":"23","author":"A Osterborg","year":"2009","unstructured":"Osterborg A, Fo\u00e0 R, Bezares RF et al (2009) Management guidelines for the use of alemtuzumab in chronic lymphocytic leukemia. Leukemia 23:1980\u20131988","journal-title":"Leukemia"},{"key":"1966_CR26","doi-asserted-by":"crossref","first-page":"4990","DOI":"10.1182\/blood.V87.12.4990.bloodjournal87124990","volume":"87","author":"BD Cheson","year":"1996","unstructured":"Cheson BD, Bennett JM, Grever M et al (1996) National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 87:4990\u20134997","journal-title":"Blood"},{"key":"1966_CR27","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.3109\/10428194.2012.664845","volume":"53","author":"L Fan","year":"2012","unstructured":"Fan L, Wang L, Zhang R et al (2012) Richter transformation in 16 of 149 Chinese patients with chronic lymphocytic leukemia. Leuk Lymphoma 53:1749\u20131756","journal-title":"Leuk Lymphoma"},{"key":"1966_CR28","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/j.1365-2141.2008.07166.x","volume":"142","author":"D Rossi","year":"2008","unstructured":"Rossi D, Cerri M, Capello D et al (2008) Biological and clinical risk factors of chronic lymphocytic leukaemia transformation to Richter syndrome. Br J Haematol 142:202\u2013215","journal-title":"Br J Haematol"},{"key":"1966_CR29","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1200\/JCO.2005.05.0187","volume":"24","author":"AM Tsimberidou","year":"2006","unstructured":"Tsimberidou AM, O\u2019Brien S, Khouri I et al (2006) Clinical outcomes and prognostic factors in patients with Richter\u2019s syndrome treated with chemotherapy or chemoimmunotherapy with or without stem-cell transplantation. J Clin Oncol 24:2343\u20132351","journal-title":"J Clin Oncol"},{"key":"1966_CR30","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1038\/leu.2009.148","volume":"23","author":"A Cortelezzi","year":"2009","unstructured":"Cortelezzi A, Pasquini MC, Gardellini A et al (2009) Low-dose subcutaneous alemtuzumab in refractory chronic lymphocytic leukaemia (CLL): results of a prospective, single-arm multicentre study. Leukemia 23:2027\u20132033","journal-title":"Leukemia"},{"key":"1966_CR31","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.3109\/10428194.2011.584991","volume":"52","author":"RF Bezares","year":"2011","unstructured":"Bezares RF, Stemelin G, Diaz A et al (2011) Multicenter study of subcutaneous alemtuzumab administered at reduced dose in patients with fludarabine-relapsed\/refractory chronic lymphocytic leukemia: final analysis. Leuk Lymphoma 52:1936\u20131941","journal-title":"Leuk Lymphoma"},{"key":"1966_CR32","doi-asserted-by":"crossref","first-page":"4079","DOI":"10.1182\/blood-2011-05-351833","volume":"118","author":"M Montillo","year":"2011","unstructured":"Montillo M, Tedeschi A, Petrizzi VB et al (2011) An open-label, pilot study of fludarabine, cyclophosphamide, and alemtuzumab in relapsed\/refractory patients with B-cell chronic lymphocytic leukemia. Blood 118:4079\u20134085","journal-title":"Blood"},{"key":"1966_CR33","doi-asserted-by":"crossref","first-page":"424","DOI":"10.3109\/10428194.2011.623258","volume":"53","author":"G Gritti","year":"2012","unstructured":"Gritti G, Reda G, Maura F et al (2012) Low dose alemtuzumab in patients with fludarabine-refractory chronic lymphocytic leukemia. Leuk Lymphoma 53:424\u2013429","journal-title":"Leuk Lymphoma"},{"key":"1966_CR34","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1182\/blood.V98.6.1979","volume":"98","author":"M Hisada","year":"2001","unstructured":"Hisada M, Biggar RJ, Greene MH et al (2001) Solid tumors after chronic lymphocytic leukemia. Blood 98:1979\u20131981","journal-title":"Blood"},{"key":"1966_CR35","doi-asserted-by":"crossref","unstructured":"Dalia S, Chavez JC, Domingo G et al (2012) Incidence of second and secondary malignancies in patients with CLL: a single institution experience. J Clin Oncol 30(suppl; abstr 6568)","DOI":"10.1200\/jco.2012.30.15_suppl.6568"},{"key":"1966_CR36","doi-asserted-by":"crossref","first-page":"E264","DOI":"10.1111\/ctr.12094","volume":"27","author":"C Puttarajappa","year":"2013","unstructured":"Puttarajappa C, Yabes J, Bei L et al (2013) Cancer risk with alemtuzumab following kidney transplantation. Clin Transplant 27:E264\u2013E271","journal-title":"Clin Transplant"},{"key":"1966_CR37","doi-asserted-by":"crossref","first-page":"981","DOI":"10.3109\/10428190109097717","volume":"42","author":"C Hercher","year":"2001","unstructured":"Hercher C, Robain M, Davi F et al (2001) A multicentric study of 41 cases of B-prolymphocytic leukemia: two evolutive forms. Leuk Lymphoma 42:981\u2013987","journal-title":"Leuk Lymphoma"},{"key":"1966_CR38","doi-asserted-by":"crossref","first-page":"169","DOI":"10.3109\/10428199909093739","volume":"33","author":"L Shvidel","year":"1999","unstructured":"Shvidel L, Shtalrid M, Bassous L, Klepfish A, Vorst E, Berrebi A (1999) B-cell prolymphocytic leukemia: a survey of 35 patients emphasizing heterogeneity, prognostic factors and evidence for a group with an indolent course. Leuk Lymphoma 33:169\u2013179","journal-title":"Leuk Lymphoma"},{"key":"1966_CR39","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1182\/asheducation-2011.1.119","volume":"2011","author":"JE Arnason","year":"2011","unstructured":"Arnason JE, Brown JR (2011) Alemtuzumab use in relapsed and refractory chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program 2011:119\u2013120","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"1966_CR40","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1200\/JCO.2011.35.9695","volume":"30","author":"AR Pettitt","year":"2012","unstructured":"Pettitt AR, Jackson R, Carruthers S et al (2012) Alemtuzumab in combination with methylprednisolone is a highly effective induction regimen for patients with chronic lymphocytic leukemia and deletion of TP53: final results of the national cancer research institute CLL206 trial. J Clin Oncol 30:1647\u20131655","journal-title":"J Clin Oncol"},{"key":"1966_CR41","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1056\/NEJM200012283432602","volume":"343","author":"H D\u00f6hner","year":"2000","unstructured":"D\u00f6hner H, Stilgenbauer S, Benner A et al (2000) Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 343:1910\u20131916","journal-title":"N Engl J Med"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-013-1966-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-013-1966-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-013-1966-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,11]],"date-time":"2020-08-11T01:12:40Z","timestamp":1597108360000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-013-1966-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11,30]]},"references-count":41,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,2]]}},"alternative-id":["1966"],"URL":"https:\/\/doi.org\/10.1007\/s00277-013-1966-z","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,11,30]]}}}